149 related articles for article (PubMed ID: 31788667)
1. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
2. Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.
Uckun FM; Mitchell LG; Qazi S; Liu Y; Zheng N; Myers DE; Song Z; Ma H; Cheng J
EBioMedicine; 2015 Jul; 2(7):649-59. PubMed ID: 26288837
[TBL] [Abstract][Full Text] [Related]
3. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.
Uckun FM; Qazi S; Ma H; Reaman GH; Mitchell LG
Integr Biol (Camb); 2015 Feb; 7(2):237-49. PubMed ID: 25567759
[TBL] [Abstract][Full Text] [Related]
4. CD22ΔE12 as a molecular target for RNAi therapy.
Uckun FM; Ma H; Cheng J; Myers DE; Qazi S
Br J Haematol; 2015 May; 169(3):401-14. PubMed ID: 25659406
[TBL] [Abstract][Full Text] [Related]
5. A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies.
Uckun FM; Qazi S; Ma H; Yin L; Cheng J
EBioMedicine; 2014 Dec; 1(2-3):141-155. PubMed ID: 25599086
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Uckun FM; Myers DE; Cheng J; Qazi S
EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
[TBL] [Abstract][Full Text] [Related]
7. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.
Ma H; Qazi S; Ozer Z; Gaynon P; Reaman GH; Uckun FM
Br J Haematol; 2012 Jan; 156(1):89-98. PubMed ID: 22017452
[TBL] [Abstract][Full Text] [Related]
8. Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in Mice.
Uckun FM; Myers DE; Ma H; Rose R; Qazi S
EBioMedicine; 2015 Apr; 2(4):306-316. PubMed ID: 26097891
[TBL] [Abstract][Full Text] [Related]
9. SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia.
Uckun FM; Qazi S
J Cancer Ther; 2014 Jan; 5(1):124-131. PubMed ID: 24851191
[TBL] [Abstract][Full Text] [Related]
10. Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.
Uckun FM; Ma H; Ishkhanian R; Arellano M; Shahidzadeh A; Termuhlen A; Gaynon PS; Qazi S
PLoS One; 2013; 8(11):e80732. PubMed ID: 24278314
[TBL] [Abstract][Full Text] [Related]
11. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.
Uckun FM; Goodman P; Ma H; Dibirdik I; Qazi S
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16852-7. PubMed ID: 20841423
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.
Uckun FM; Myers DE; Qazi S; Ozer Z; Rose R; D'Cruz OJ; Ma H
J Clin Invest; 2015 Mar; 125(3):1006-18. PubMed ID: 25621496
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Uckun FM; Sather H; Gaynon P; Arthur D; Nachman J; Sensel M; Steinherz P; Hutchinson R; Trigg M; Reaman G
Leuk Lymphoma; 1997 Nov; 27(5-6):445-57. PubMed ID: 9477126
[TBL] [Abstract][Full Text] [Related]
14. CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL.
Qazi S; Uckun FM
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900389
[TBL] [Abstract][Full Text] [Related]
15. Absence of Genomic
Qazi S; Ma H; Uckun FM
Int J Mol Med Sci; 2013 Jul; 3(9):72-82. PubMed ID: 24478816
[TBL] [Abstract][Full Text] [Related]
16. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
19. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
